FDA Investigator Nancy L Rolli

Nancy L Rolli has inspections in 6 countries as of 22 Sep 2023. Nancy L Rolli has collaborated with a combinined 3464 experts on various inspections, contributing to compliance and improvement across diverse sectors.

Investigator Details

Number of Inspected Sites:
40
Last Inspection Date:
22 Sep 2023
Investigator Role:
FDA Investigator
Redica ID:
Country:
United States of America, Germany, France, United Kingdom of Great Britain and Northern Ireland, Canada
Co-Investigator(s):
Addam S Reynolds, Adetutu M Gidado, Alberto A Viciedo, Allen Lou, Amy L Singer, Amy M Codella, Amy M Cramer, Ana S Cabrera, Ann Marie Montemurro, Annemarie B Randow, Annemarie Bodnar, Annet R Rajan, Anthony J Donato, Arie C Menachem, Arsen Karapetyan, Atul J Agrawal, Barbara J Maulfair, Barbara J Wilimczyk, Barbara Jwilimczyk Macri, Barbara L Rellahan, PhD, Bei Yu, Benjamin J Smith, Bijoy Panicker, Brian J Ryan, Brian S Keefer, Bruce H Mccullough, Byungja E Marciante, Cara M Minelli, Carla J Lundi, Carr Sharpe, Caryn M Mcnab, Charles L Zhou, Christina P Burkhart, Constantin Y Philopoulos, Cynthia F Kleppinger, MD, Daniel J Grabicki, David A Oluwo, Dawn L Wydner, Deborah B Nixon, Dennis Cantellops Paite, Donald L Lech, Donna Mwilliams Hill, Douglas C Kovacs, Dr. Zhou Chen (nmi), MD PhD, Edward D Mcdonald, Edwin Melendez, Emest F Bizjak, Emmanuel J Ramos, Eric J Cunningham, Eric Rothschild, Erin D Mccaffery, Esteban Beltran, Frank J Marciniak, Fred Razzaghi, Frederick Razzaghi, Gayle S Lawson, Ginger M Sykes, Guerlain Ulysse, Helen B Ricalde, Helen Verdel, Ifueko Osemwota, Ivan E Reyes, Jacqueline Mdiaz Albertini, James R Birkenstamm, Jamie M Du, Jane S Wernberg, Jean Blackston Hill, Jean M Kelahan, Jean M Mulinde, MD, Jeffrey D Meng, Jeffrey J Ebersole, Jennifer M Gogley, Joanne Heim, Joel D Hustedt, Joey V Quitania, John A Gonzalez, Jonee J Mearns, Jose Acruz Gonzalez, Joseph A Piechocki, Joseph F Mcginnis, RPh, Joshua P Wireman, Joy R Kelna, Joy Rkozlowski Klena, Julie A Rorberg, Julie A Stocklin, Julie D Bringger, Justine M Corson, Karen E D'orazio, Katherine D Adams, Katherine E Jacobitz, Keith M Reilly, Kelli F Dobilas, Kenneth H Williams, Kenneth M Gordon, Kevin A Gonzalez, Kevin D Kallander, Kham Phommachanh, Kim Lthomas Cruse, Kinh Q Mac, Kristy A Zielny, Kumar G Janoria, Larry K Austin, Laura Fontan, MS, Lauren L Vajo, Li Li, Liatte Kreuger, PharmD, Liming Zhang, Linda K Cline, Linda Thai, Lisa B Hall, Lisa M Bellows, Louis B Cencetti, Lydia Irosas Marty, Marcus F Yambot, Marea K Harmon, Margaret M Annes, Margaret M Sands, Maria Estrella, Mark R Mcclain, Matthew A Spataro, Matthew B Casale, Matthew J Johnson, Matthew Sparato, Maya M Davis, Melba T Rivera, Melba Trivera Clavell, Melissa D Ray, Meredith L Sheridan, Meyer J Slobotsky, Michael A Charles, Michael P Sheehan, Michael R Goga, Michael R Klapal, Michael Serrano, Michael W Burd, Michele L Obert, Mihaly S Ligmond, Mohsen Rajabi Abhari, FDA, Mra M Barbosar, Mra Munizn, Nancy A Saxenian, Nancy A Saxenian Emmons, Nancy G Schmidt, Nancy M Espinal, Nancy Roll, Nicholas A Violand, Niketa Patel, Nina Yang, Niraj Mehta, Parul M Patel, Patrick C Klotzbuecher, Paul L Bellamy, Paul Mouris, Peter R Lenahan, Philip F Istafanos, DMV, MS, Prabhu P Raju, Qin Xu, Rebecca E Dombrowski, Regina T Brown, Robert M Barbosa, Rochelle K Kimmel, Russell J Glapion, Saied A Asbagh, Samantha J Bradley, Sandra Kershaw, Sanket N Patel, Sarah Adella Fave, Shirley H Isbill, Shirley S Wen, Shirnette D Ferguson, Sidney B Priesmeyer, Sinai Davis, Sripal R Mada, PhD, Stephen J Mottola, Sue Lee Chan, Susanna E Ford, Analyst, Tajah L Blackburn, Tamil Arasu, PhD, Tara G Bizjak, Tara R Gooen, Terri L Dodds, Thao T Kwan, Thomas J Arista, Thuy T Nguyen, LCDR, Timothy T Kapsala, Valerie C Reed, Virgilio F Pacio, CSO, Vlada Matusovsky, Wayne E Seifert, Wayne J Meyer, William Chang, William R Chang, Xikui Chen (nmi), PhD, Yasamin Ameri, Yumi J Hiramine, Yvins Dezan, Zachary A Bogorad

Nancy L Rolli's Documents

Publish Date Document Type Title
February, 2010 FDA 483 Gilead Sciences, Inc. - Form 483, 2010-02-12
June, 2003 EIR Merck & Co., Inc. - EIR, 2003-06-06
February, 2000 FDA 483 Response Merck, Inc. - Form 483R, 2000-03-20
April, 2000 FDA 483 Response Bayer Aktiengesellschaft - Form 483R, 2000-05-10
August, 2006 EIR Actavis Totowa LLC - EIR, 2006-08-10
January, 2001 FDA 483 Hoffmann-La Roche Inc. - Form 483, 2001-01-31
November, 2001 FDA 483 Actavis Totowa LLC - Form 483, 2001-11-29
March, 2003 EIR Apotex Inc. - EIR, 2003-03-27
April, 2000 EIR Bayer Aktiengesellschaft - EIR, 2000-10-06
March, 2003 EIR Apotex Inc. - EIR, 2003-03-27
May, 2002 EIR Hikma Pharmaceuticals USA, Inc. - EIR, 2002-05-02
February, 2002 EIR Pacon Manufacturing Corporation - EIR, 2002-02-13
October, 2000 EIR Merck Sharp & Dohme LLC - EIR, 2000-10-13
February, 2010 EIR Gilead Sciences, Inc. - EIR, 2010-02-12
May, 2002 FDA 483 Hikma Pharmaceuticals USA, Inc. - Form 483, 2002-05-02
August, 2006 FDA 483 Actavis Totowa LLC - Form 483, 2006-08-10
February, 2000 FDA 483 Merck, Inc. - Form 483, 2000-02-25
May, 2001 FDA 483 Cosette Pharmaceuticals, Inc. - Form 483, 2004-05-24
August, 2001 FDA 483 Barr Laboratories, Inc. - Form 483, 2001-08-13
February, 2000 FDA 483 Merck, Inc. - Form 483, 2000-02-25
November, 2001 EIR Actavis Totowa LLC - EIR, 2001-11-29
June, 2002 FDA 483 The P.F. Laboratories Inc. - Form 483, 2002-06-10
February, 2004 FDA 483 Response Pharmaceutical Formulations Inc. - Form 483R, 2004-03-08
February, 2004 FDA 483 Pharmaceutical Formulations Inc. - Form 483, 2004-02-09
November, 2001 FDA 483 Response Actavis Totowa LLC - Form 483R, 2001-12-10
January, 2001 EIR Hoffmann La Roche Inc - EIR, 2001-01-31
June, 2003 FDA 483 Merck, Inc. - Form 483, 2003-06-13
April, 2003 EIR Bimeda-MTC Animal Health - EIR, 2003-04-03
April, 2001 EIR Able Laboratories Inc. - EIR, 2001-04-10
May, 2001 EIR Cosette Pharmaceuticals, Inc. - EIR, 2001-05-10
August, 2000 EIR Hikma Pharmaceuticals USA, Inc. - EIR, 2000-08-23
August, 2001 EIR Barr Laboratories, Inc. - EIR, 2001-08-13
April, 2001 FDA 483 Able Laboratories Inc. - Form 483, 2001-04-10
February, 2000 EIR Merck, Inc. - EIR, 2000-02-25
April, 2000 FDA 483 Schering AG - Form 483, 2000-04-14
April, 2003 FDA 483 Bimeda-MTC Animal Health - Form 483, 2003-04-03
January, 2001 FDA 483 Response Hoffmann La Roche Inc - Form 483R, 2001-02-21
March, 2003 FDA 483 Response Apotex Inc. - Form 483R, 2003-06-10
July, 2005 FDA 483 Able Laboratories, Inc. - Form 483, 2005-07-06

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more